Zacks Investment Research upgraded shares of Advanz Pharma (OTCMKTS:CXRXF) from a sell rating to a hold rating in a research report released on Monday, Zacks.com reports.

According to Zacks, “Advanz Pharma Corp. is a specialty pharmaceutical company. It operates primarily in Bridgetown, Barbados; London, England and Mumbai, through its subsidiaries. Advanz Pharma Corp., formerly known as Concordia International Corp., is based in LONDON, UNITED KINGDOM. “

CXRXF has been the subject of several other research reports. ValuEngine raised Advanz Pharma from a sell rating to a hold rating in a research note on Friday, March 1st. Bloom Burton reissued a hold rating on shares of Advanz Pharma in a research note on Friday, March 15th.

Shares of CXRXF opened at $13.17 on Monday. Advanz Pharma has a 12 month low of $13.14 and a 12 month high of $68.40. The company has a quick ratio of 1.79, a current ratio of 2.10 and a debt-to-equity ratio of 4.50.

Advanz Pharma (OTCMKTS:CXRXF) last released its quarterly earnings results on Thursday, March 14th. The company reported ($1.74) earnings per share (EPS) for the quarter. The firm had revenue of $117.57 million during the quarter. On average, analysts forecast that Advanz Pharma will post -2.96 EPS for the current year.

About Advanz Pharma

ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.

Further Reading: How is the S&P 500 index different from the DJIA?

Get a free copy of the Zacks research report on Advanz Pharma (CXRXF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Advanz Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanz Pharma and related companies with MarketBeat.com's FREE daily email newsletter.